BioPharma Credit PLC

BPCP

GB00BDGKMY29

Closed End Funds

Market Closed - London S.E. Other stock markets 11:35:13 2024-05-28 EDT			5-day change	1st Jan Change
0.84 ^USD	-0.71%		-2.33%	0.00%

05-02	BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	MT
05-02	BioPharma Credit agrees USD400 million loan for oncology firm Novacure	AN

Biopharma Credit plc Appoints Duncan Budge as Director

March 27, 2017 at 05:19 am

Artemis Alpha Trust plc announced that Duncan Budge, chairman and non-executive director of the company, has been appointed as a director of BioPharma Credit PLC.

Latest news about BioPharma Credit PLC

BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	05-02	MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure	05-02	AN
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals	04-24	MT
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals	04-24	AN
BioPharma Credit PLC Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
BioPharma Credit net asset value ticks up but total payout lower	03-27	AN
BioPharma Credit Board, Investment Manager Propose Changes to Discount Control Mechanism	03-27	MT
BioPharma Credit Logs Lower FY23 Net Income Return on Ordinary Activities	03-27	MT
Tranche Update on BioPharma Credit PLC's Equity Buyback Plan announced on May 31, 2023.	03-27	CI
Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024	03-21	CI
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	02-13	AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	02-13	MT
BioPharma Credit PLC Declares Interim Special Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024	02-08	CI
BioPharma Credit PLC Declares Ordinary Interim Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024	02-08	CI
Jefferies Downgrades BioPharma Credit to Hold from Buy	02-07	MT
Jefferies cuts BioPharma Credit to 'hold'	02-07	AN
Barratt takes over Redrow in GBP2.5 billion deal	02-07	AN
BioPharma Credit to receive partial prepayment of loan	02-06	AN
BioPharma Credit to fund LumiraDx ahead of acquisition by Roche	01-02	AN
BioPharma Credit notes loan agreement amendment by LumiraDx	12-12	AN
BioPharma Credit notes AbbVie takeover of investee ImmunoGen	12-01	AN
Biopharma Credit plc Declares Special Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024	11-29	CI
BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024	11-29	CI
BioPharma Credit says liquidity covenant in loan deal waived	23-10-12	AN
BioPharma Credit PLC Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI

BioPharma Credit PLC is a United Kingdom-based specialist debt investor to the life sciences industry. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. It seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. The Company may also invest in equity issued by a life sciences company, acquired directly from the life sciences company or in the secondary market. It will seek to create a diversified portfolio of investments by investing across a range of different forms of debt assets issued by a variety of borrowers. It has two wholly owned subsidiaries: BPCR Limited Partnership and BPCR GP Limited. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors, LP.

Sector

Closed End Funds

Calendar

2024-06-12 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.84

Average target price

Consensus

Sector Closed End Funds

	1st Jan change	Capi.
BIOPHARMA CREDIT PLC	0.00%	1.03B
ARES CAPITAL CORPORATION	+6.54%	13.12B
PERSHING SQUARE HOLDINGS, LTD.	+13.15%	9.66B
FS KKR CAPITAL CORP.	+0.75%	5.63B
SPROTT PHYSICAL URANIUM TRUST FUND	+6.69%	5.48B
PIMCO DYNAMIC INCOME FUND	+6.91%	5.25B
SPROTT PHYSICAL SILVER TRUST	+32.80%	4.92B
SPROTT PHYSICAL GOLD AND SILVER TRUST	+23.89%	4.72B
MACQUARIE KOREA INFRASTRUCTURE FUND	+1.61%	4.06B
3I INFRASTRUCTURE PLC	+3.27%	3.89B

Closed End Funds